TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04797442

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WST01 strain product
Description: orally given WST01 strain product, added onto lifestyle. The specific ingredients are the optimized Akkermansia muciniphila WST01 strain powder with maximum live bacteria of 5\*10\^10 CFU/g (1 g/pack, 3 packs QD, 20-30 min after breakfast)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo powder
Description: orally given placebo powder (the specific ingrdients are the excipients of the WST01 strain powder), added onto lifestyle. (3 packs of placebo powder QD, 20-30 min after breakfast)
Study: NCT06194084

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Two-sequence of durian pulp doses (100 g and 200 g)
Description: Participants first go through an initial washout maintaining a low-fiber diet for 14 days. After washout, participants will be instructed to consume 100 grams of durian pulp every day following their breakfast or dinner for 1 week. Participants will then continue to consume 200 grams of durian pulp every day during the 2nd week of intervention and then will go through another washout for 2 weeks.
Study: NCT04908280

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: 1.5% cream; Ruxolitinib cream will be applied topically twice daily to areas with active lesions.
Study: NCT04924933

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Computerised associative memory task using abstract words and landscape photographs
Description: Two test sessions using the computerised associative memory task will be performed by the two groups (patients and control subjects). The first session will consist of the encoding of 56 associations between a word and a photograph and the recall of half of them (28) 30 minutes later by the mean of a matching task and a recognition task. The second session consists of the recall of the other half of the associations (28) 72 hours after the encoding phase, using the same procedure (matching task and recognition task). Performance obtained by patients and by healthy volunteers will then be compared.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Computerised associative memory task using abstract words and landscape photographs
Description: Two test sessions using the computerised associative memory task will be performed by the two groups (patients and control subjects). The first session will consist of the encoding of 56 associations between a word and a photograph and the recall of half of them (28) 30 minutes later by the mean of a matching task and a recognition task. The second session consists of the recall of the other half of the associations (28) 72 hours after the encoding phase, using the same procedure (matching task and recognition task). Performance obtained by patients and by healthy volunteers will then be compared.
Study: NCT04741230

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gebauer Lenticule
Description: The Gebauer™ Lenticule corneal implant device is a custom-made device intended for patients suffering from keratoconus or post-LASIK ectasia. The device is expected to reinforce and stabilize the patient's cornea, so that a more consistent refraction is induced and a penetrating human cornea donor transplantation may be avoided or postponed.
Study: NCT05896215

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KNP2002
Description: Dairy topical administration for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KNP2002
Description: Dairy topical administration for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KNP2002
Description: Dairy topical administration for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo of KNP2002
Description: Dairy topical administration for 12 weeks
Study: NCT05171894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemopfin+Green Light
Description: All qualified subjects randomized to Hemoporfin PDT treatment to receive up to 3 cycles of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemopfin+Green Light
Description: All qualified subjects randomized to Hemoporfin PDT treatment to receive up to 3 cycles of treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hemopfin+Green Light
Description: All qualified subjects randomized to Hemoporfin PDT treatment to receive up to 3 cycles of treatment.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle+Green Light
Description: All qualified subjects randomized to vehicle PDT treatment to receive up to 3 cycles of treatment.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle+Green Light
Description: All qualified subjects randomized to vehicle PDT treatment to receive up to 3 cycles of treatment.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle+Green Light
Description: All qualified subjects randomized to vehicle PDT treatment to receive up to 3 cycles of treatment.
Study: NCT05506592

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dermatological product
Description: cosmetic shampoo

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: dermatological product
Description: cosmetic shampoo
Study: NCT06295016

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High-intensity intensive training
Description: Participants will conduct a 3-weeks of 130% progressive high-intensity intensive training (increasing by 10% each week).~Week 1: Increase training to 110% of participants' regular training volume. Week 2: Increase training to 120% of participants' regular training volume. Week 3: Increase training to 130% of participants' regular training volume.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taper
Description: Participants will conduct a 1-week taper phase by gradually reducing to 55% of their regular training volume.~Day 1: Decrease current training volume by 20%. Day 2: Decrease current training volume by 15%. Day 3: Decrease current training volume by 10%. Day 4: Decrease current training volume by 10%. Day 5: Decrease current training volume by 10%. Day 6: Decrease current training volume by 5%. Day 7: Decrease current training volume by 5%.
Study: NCT04520516

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active VAGUSTIM device
Description: Settings: 25 Hz stimulation, 100 microsec pulse width, intensity escalation up to 8 mA or below if tingling sensation, 20 min/day of stimulation in one daily session

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham VAGUSTIM device
Description: The sham device : no electrical signal for VNS will be delivered.
Study: NCT05401227

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine during an MRI

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: Ketamine during an MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine during an MRI

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: Ketamine during an MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine during an MRI

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: Ketamine during an MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ts-134
Description: 4 days of TS-134 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ts-134
Description: 4 days of TS-134 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ts-134
Description: 4 days of TS-134 20 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 days of placebo TS-134

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 days of placebo TS-134

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 days of placebo TS-134
Study: NCT05459389

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: targeted antibiotics therapy
Description: targeted antibiotics therapy guided by resistance genotyping (n=24)
Study: NCT06378294

Intervention type: PROCEDURE
Intervention: Mastectomy
Description: Adjuvant postmastectomy radiotherapy
Study: NCT04912037

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: artificial intelligence assistance system
Description: the artificial intelligence assistance system can indicate abnormal lesions and real-time withdrawal speed, and feedback the overspeed percentage.
Study: NCT05948410

Intervention type: BEHAVIORAL
Intervention: The State-Trait Anxiety Inventory (STAI)
Description: The State-Trait Anxiety Inventory (STAI) is a psychological inventory consisting of 40 self-report items on a 4-point Likert scale. The STAI measures two types of anxiety - state anxiety and trait anxiety. Higher scores are positively correlated with higher levels of anxiety.

Intervention type: BEHAVIORAL
Intervention: Perceived Stress Scale
Description: The Perceived Stress Scale (PSS) is the most widely used psychological instrument for measuring the perception of stress. It is a measure of the degree to which situations in one's life are appraised as stressful. Items were designed to tap how unpredictable, uncontrollable, and overloaded respondents find their lives. The scale also includes a number of direct queries about current levels of experienced stress. PSS scores are obtained by reversing responses (e.g., 0 = 4, 1 = 3, 2 = 2, 3 = 1 \& 4 = 0) to the four positively stated items (items 4, 5, 7, \& 8) and then summing across all scale items. A short 4 item scale can be made from questions 2, 4, 5 and 10 of the PSS 10 item scale

Intervention type: BEHAVIORAL
Intervention: Visual Analog Scale
Description: The visual analogue scale (VAS) is a psychometric response scale that can be used in questionnaires. It is a measurement instrument for subjective characteristics or attitudes that cannot be directly measured. When responding to a VAS item, respondents specify their level of agreement to a statement by indicating a position along a continuous line between two end points.
Study: NCT05792670

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Changing mechanic ventilatation parameters
Description: The tidal volume and respiration frequency were determined by the MV according to patient's age and weight with end-tidal CO2 levels of 30-35 mmHg. Standard ventilation mode was defined as 8-10 mL/kg tidal volume and 10-15 respirations/min. During HV mode, the tidal volume was decreased to 6-8 mL/kg and the frequency was increased to 15-18 respirations/min. No changes were made in the inspiratory expiratory ratio (1:2), FiO2, and positive end-expiratory pressure (PEEP) parameters.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Changing mechanic ventilatation parameters
Description: The tidal volume and respiration frequency were determined by the MV according to patient's age and weight with end-tidal CO2 levels of 30-35 mmHg. Standard ventilation mode was defined as 8-10 mL/kg tidal volume and 10-15 respirations/min. During HV mode, the tidal volume was decreased to 6-8 mL/kg and the frequency was increased to 15-18 respirations/min. No changes were made in the inspiratory expiratory ratio (1:2), FiO2, and positive end-expiratory pressure (PEEP) parameters.
Study: NCT05686473

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Program of psychoeducation of parents and professionals
Description: The program consists of a standardized manual-based treatment package as an easily accessible treatment tool for use by professionals in the specialist health services, who have treatment responsibilities for children diagnosed with FASD in Norway.~The intervention program will last for about 2 months and includes eight sessions, including six digitally based, interactive psychoeducational sessions.~Topics will be:~1. General information about FASD~2. Intervention strategies in kindergartens/schools for children with FASD~3. Families living with FASD - activities of daily living~4. Self-regulatory deficits - how to cope~5. Executive functions in daily life~6. Social development in children with FASD~7. Guidance in social settings~8. Challenging behavior - what can be done
Study: NCT05014516

Intervention type: DRUG
Intervention: 129Xenon gas
Description: Observational
Study: NCT04894786

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mulligan Internal Rotation Mobilization
Description: Mulligan Internal Rotation Mobilization (MIRM) Sleeper Stretch The therapist places a web of his one hand around patient's axilla and thumb of another hand in the bent elbow and the glide will be applied to the head of the humerus down in the glenoid fossa using thumb while stabilizing the scapula with another hand. Therapist will ensures that the other hand is stabilizing up and inwards. While this distraction is taking place the patient internally rotated his shoulder with the help of another hand, at the same time his affected upper arm will abduct by therapist abdomen distracting the head of the humerus laterally. The hand in axilla acts as a fulcrum. Mulligan MWM will be applied for 3 days alternate days by following the rule of 3
Study: NCT06412601

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RPM
Description: remote patient monitoring by clinic staff

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: app
Description: use of Happy Bob phone app

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: app
Description: use of Happy Bob phone app
Study: NCT04894786

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Post Isometric Relaxation Technique
Description: Post Isometric Relaxation Technique (PIRT) Sleeper Stretch The subject will be positioned supine on the treatment table with the shoulder and elbow, at 90 degree of abduction and flexion. The shoulder will be stabilized at the acromion process with one hand, and the other hand will be used to passively move the arm into internal rotation until the first barrier of motion will reached. The subject will be then instructed to perform a 5second isometric contraction of approximately 25% maximal effort in the direction of external rotation, against an opposing force provided at the distal forearm. Following the contraction, the subject will be instructed to internally rotate the arm toward the ground as a 30-second active assisted stretch will be applied. The subject will be instructed to relax, and a new movement barrier will then engage.
Study: NCT06117800

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TeamSTEPPS
Description: Team Tools and Strategies to Enhance Performance and Patient Safety (TeamSTEPPS®) is an evidence-based framework that has been used in interprofessional education programs to develop and train newly graduate nurses to deal with difficult clinical situations.
Study: NCT06121336

Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma levels of BD-tau
Description: Plasma levels of BD-tau will be assessed using a single-molecule array assay.
Study: NCT05582811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dose Riociguat 2,5 or 5mg
Description: A selective stimulator of soluble guanylate cyclase (sGC)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Riociguat
Description: A selective stimulator of soluble guanylate cyclase (sGC)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04827914

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Care
Description: Smokers in the enhanced care group will receive live counseling (either in person or telehealth consult) while hospitalized combined with post-hospital discharge automated calls using interactive voice recognition (IVR) technology.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Basic Care
Description: Smokers assigned to the basic care group will only receive the post-discharge IVR phone calls.
Study: NCT06566079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ISM6331
Description: Dosage form: Capsule for oral administration.~Frequency of administration: Once daily overall of treatment.
Study: NCT06089954

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: private web-portal eHealth disclosure of genetic results
Description: The intervention involves delivering actionable genetic research results to participants via a secure, private web-portal.
Study: NCT05766605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin, Leucovorin, fluorouracil
Description: Oxaliplatin(130 mg per square body surface area), Leucovorin(400 mg per square body surface area), and fluorouracil(2800 mg per square body surface area) were used for monthly transhepatic arterial.~infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lobaplatin, Raltitrexed
Description: Lobaplatin(50 mg per square body surface area) and Raltitrexed(3 mg per square body surface area) were used for monthly transhepatic arterial infusions.
Study: NCT06584812

Intervention type: DRUG
Group type: OTHER
Intervention: Tiprogrel
Description: Period 1: Dose 1 Tiprogrel, loading dose of Tiprogrel followed by daily maintenance dose until Day 8.

Intervention type: DRUG
Group type: OTHER
Intervention: Tiprogrel
Description: Period 2: Dose 2 Tiprogrel ; loading dose of Tiprogrel followed by daily maintenance dose until Day 8.

Intervention type: DRUG
Group type: OTHER
Intervention: Clopidogrel
Description: Period 3: Clopidogrel; loading dose of Clopidogrel followed by daily maintenance dose until Day 8.

Intervention type: DRUG
Group type: OTHER
Intervention: Ticagrelor
Description: Period 4: Ticagrelor; loading dose of Ticagrelor followed by daily maintenance dose until Day 8.
Study: NCT06005948

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: The dynamic neuromuscular stabilization group will receive developmental postures based on developmental kinesiology. It will involve a supine 3month Position, side-lying Position, Quadruped, oblique sitting, bear position, squat Position. Each position will be performed for 30-60 s for five reps, active exercise 5-10 reps under supervision for two days/week, and unsupervised for 3 days/week for 8 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: No intervention will be made.
Study: NCT05889013

Intervention type: DEVICE
Intervention: Nasal Nitric Oxide testing
Description: Collection of already performed clinical data and nNO testing
Study: NCT06089954

Intervention type: OTHER
Group type: OTHER
Intervention: eHealth education intervention (web or chatbot)
Description: The intervention involves pre-disclosure education via an eHealth intervention (web or chatbot). The intervention will review the types of actionable results being returned, the method of return, the differences between research and clinical testing, the need for confirmation testing and the benefits, risks and limitations of receiving actionable genetic research results and study steps and procedures.
Study: NCT04818814

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation App
Description: Listening to audio-guided meditation sessions using a mobile app.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Engagement and Distraction App
Description: Listening to engaging and distracting videos of interest to the participant using a mobile app.
Study: NCT06342102

Intervention type: PROCEDURE
Intervention: PENG + LFCN block
Description: The PENG block was performed under ultrasound guidance. After skin disinfection, the needle was advanced between the psoas tendon and pubic ramus where 20 mL of 0.5% ropivacaine were injected. The LFCN block was performed following the PENG block.10 ml of 0.5% ropivacaine were injected near the nerve into the fat-filled flat tunnel (FFFT) located at the level of the superior anterior iliac spine and lateral to the sartorius muscle.

Intervention type: PROCEDURE
Intervention: FIC block
Description: FICB was performed under ultrasound guidance. The needle was advanced above the fascia iliaca and 20 mL of 0.5% ropivacaine were injected
Study: NCT06089954

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: eHealth education intervention (web or chatbot)
Description: The intervention involves pre-disclosure education via an eHealth intervention (web or chatbot). The intervention will review the types of actionable results being returned, the method of return, the differences between research and clinical testing, the need for confirmation testing and the benefits, risks and limitations of receiving actionable genetic research results and study steps and procedures.
Study: NCT06060002

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Group A - Stent exchange if cholecystectomy dated beyond 3 months
Description: Stent removal and cholangiogram and stone clearance (if recurrent stone/s is/are found). Stent exchange if cholecystectomy dated beyond 3 months

Intervention type: DIAGNOSTIC_TEST
Group type: SHAM_COMPARATOR
Intervention: Group B - Diagnostic EUS/MRCP/USG abdomen and LFT at 3 months
Description: Diagnostic EUS/MRCP/USG abdomen and LFT at 3 months to see recurrence of CDL. ERC and stone clearance (if recurrent stone/s found on EUS/MRCP/USG abdomen)
Study: NCT05273242

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate Injection
Description: * Artesunate: 2.4 mg/kg/dose at 0 hours, 12 hours, and 24 hours and thereafter every 24 hours; IV injection; duration of treatment 7 days. This is the standard dose recommended for the treatment of severe malaria.~* Infliximab: 5 mg/kg/dose (once only), single IV infusion over 2 hours. This is the standard dose that is given repeatedly for the treatment of psoriasis.~* Imatinib: 400 mg/dose; orally once daily; duration of treatment 14 days. This is the standard maintenance dose which is at the lower end of that used for several years in the treatment of hematological malignancies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate Injection
Description: * Artesunate: 2.4 mg/kg/dose at 0 hours, 12 hours, and 24 hours and thereafter every 24 hours; IV injection; duration of treatment 7 days. This is the standard dose recommended for the treatment of severe malaria.~* Infliximab: 5 mg/kg/dose (once only), single IV infusion over 2 hours. This is the standard dose that is given repeatedly for the treatment of psoriasis.~* Imatinib: 400 mg/dose; orally once daily; duration of treatment 14 days. This is the standard maintenance dose which is at the lower end of that used for several years in the treatment of hematological malignancies.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate Injection
Description: * Artesunate: 2.4 mg/kg/dose at 0 hours, 12 hours, and 24 hours and thereafter every 24 hours; IV injection; duration of treatment 7 days. This is the standard dose recommended for the treatment of severe malaria.~* Infliximab: 5 mg/kg/dose (once only), single IV infusion over 2 hours. This is the standard dose that is given repeatedly for the treatment of psoriasis.~* Imatinib: 400 mg/dose; orally once daily; duration of treatment 14 days. This is the standard maintenance dose which is at the lower end of that used for several years in the treatment of hematological malignancies.